- Home
- NIVF vs SBFM Comparison
NIVF vs SBFM Comparison
Compare NIVF & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- SBFM
- Stock Information
- Founded
- NIVF 2011
- SBFM 2006
- Country
- NIVF Thailand
- SBFM United States
- Employees
- NIVF N/A
- SBFM N/A
- Industry
- NIVF
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- SBFM Health Care
- Exchange
- NIVF NYSE
- SBFM Nasdaq
- Market Cap
- NIVF 2.1M
- SBFM 6.6M
- IPO Year
- NIVF N/A
- SBFM N/A
- Fundamental
- Price
- NIVF $0.87
- SBFM $1.47
- Analyst Decision
- NIVF
- SBFM Strong Buy
- Analyst Count
- NIVF 0
- SBFM 1
- Target Price
- NIVF N/A
- SBFM $15.00
- AVG Volume (30 Days)
- NIVF 3.7M
- SBFM 183.9K
- Earning Date
- NIVF 01-01-0001
- SBFM 08-15-2025
- Dividend Yield
- NIVF N/A
- SBFM N/A
- EPS Growth
- NIVF N/A
- SBFM N/A
- EPS
- NIVF N/A
- SBFM N/A
- Revenue
- NIVF $5,433,375.00
- SBFM $36,234,578.00
- Revenue This Year
- NIVF N/A
- SBFM $192.48
- Revenue Next Year
- NIVF N/A
- SBFM N/A
- P/E Ratio
- NIVF N/A
- SBFM N/A
- Revenue Growth
- NIVF 5.79
- SBFM 35.51
- 52 Week Low
- NIVF $0.85
- SBFM $1.17
- 52 Week High
- NIVF $656.00
- SBFM $7.60
- Technical
- Relative Strength Index (RSI)
- NIVF 30.60
- SBFM 48.32
- Support Level
- NIVF $0.85
- SBFM $1.42
- Resistance Level
- NIVF $1.24
- SBFM $1.75
- Average True Range (ATR)
- NIVF 0.15
- SBFM 0.13
- MACD
- NIVF 0.04
- SBFM 0.00
- Stochastic Oscillator
- NIVF 2.28
- SBFM 22.22
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.